Toward precision phenotyping of multiple sclerosis
The classification of multiple sclerosis (MS) has been established by Lublin in 1996 and
revised in 2013. The revision includes clinically isolated syndrome, relapsing-remitting …
revised in 2013. The revision includes clinically isolated syndrome, relapsing-remitting …
Toward identifying key mechanisms of progression in multiple sclerosis
L Husseini, A Geladaris, MS Weber - Trends in Neurosciences, 2024 - cell.com
A major therapeutic goal in the treatment of multiple sclerosis (MS) is to prevent the
accumulation of disability over an often decades-long disease course. Disability progression …
accumulation of disability over an often decades-long disease course. Disability progression …
[HTML][HTML] Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration
S Thakolwiboon, EA Mills, J Yang, J Doty, MI Belkin… - Frontiers in …, 2023 - frontiersin.org
Aging is associated with a progressive decline of innate and adaptive immune responses,
called immunosenescence. This phenomenon links to different multiple sclerosis (MS) …
called immunosenescence. This phenomenon links to different multiple sclerosis (MS) …
Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO. MS cohort): Age is a key contributor to presentation
F Dahlke, DL Arnold, P Aarden… - Multiple Sclerosis …, 2021 - journals.sagepub.com
Background: The Oxford Big Data Institute, multiple sclerosis (MS) physicians and Novartis
aim to address unresolved questions in MS with a novel comprehensive clinical trial data …
aim to address unresolved questions in MS with a novel comprehensive clinical trial data …
Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem …
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that
affects nearly 2.8 million people each year. MS distinguishes three main types: relapsing …
affects nearly 2.8 million people each year. MS distinguishes three main types: relapsing …
Neuroaxonal and glial markers in patients of the same age with multiple sclerosis
FC Loonstra, LRJ de Ruiter… - Neurology …, 2022 - AAN Enterprises
Background and Objectives The specificity of novel blood biomarkers for multiple sclerosis
(MS)–related neurodegeneration is unclear because neurodegeneration also occurs during …
(MS)–related neurodegeneration is unclear because neurodegeneration also occurs during …
Treatment discontinuation in older people with multiple sclerosis
W Zhu, Z Xia - Current Opinion in Neurology, 2024 - journals.lww.com
The available clinical evidence examining DMT discontinuation in older people with MS
remains inconclusive. More robust evidence from clinical trials and real-world data will be …
remains inconclusive. More robust evidence from clinical trials and real-world data will be …
[HTML][HTML] Effectiveness and cost-effectiveness of 360 disease-modifying treatment escalation sequences in multiple sclerosis
MM Versteegh, SA Huygens, BWH Wokke, J Smolders - Value in Health, 2022 - Elsevier
Objectives The rapid expansion in treatment options for relapsing-remitting multiple
sclerosis (RRMS) of the past decade requires clinical decision making on the sequential …
sclerosis (RRMS) of the past decade requires clinical decision making on the sequential …
[HTML][HTML] The economic and humanistic burden of pediatric-onset multiple sclerosis
N Greene, L Araujo, C Campos, H Dalglish… - Journal of Health …, 2022 - ncbi.nlm.nih.gov
Background: Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the
central nervous system. Pediatric-onset MS (POMS), defined as onset of MS before 18 years …
central nervous system. Pediatric-onset MS (POMS), defined as onset of MS before 18 years …
[HTML][HTML] Modeling the cost-utility of treatment sequences for multiple sclerosis
S Huygens, M Versteegh - Value in Health, 2021 - Elsevier
Objectives Most patients with multiple sclerosis (MS) switch between disease-modifying
therapies (DMTs) during their lifetime. Our aim was to develop an MS cost-utility model that …
therapies (DMTs) during their lifetime. Our aim was to develop an MS cost-utility model that …